Glenmark gets US approval for migraine drug

Zolmitriptan Tablets and Zolmitriptan ODT are indicated for the acute treatment of migraine headaches in adults

Press Trust of India New Delhi
Last Updated : May 15 2013 | 3:57 PM IST
Glenmark Pharmaceuticals Ltd today said its subsidiary has received approval from the US health regulator to sell generic versions of AstraZeneca's Zomig and Zomig ZMT tablets, a migraine drug, in the American market.

Glenmark Generics Inc, a subsidiary of Glenmark, has received approval from US Food and Drug Administration (USFDA) for Zolmitriptan tablets and Zolmitriptan Orally Disintegrating tablets, Glenmark said in a statement.

"Glenmark will commence distribution of the product immediately," the Mumbai-based firm said.

Also Read

Zolmitriptan Tablets and Zolmitriptan ODT are indicated for the acute treatment of migraine headaches in adults.

According to IMS Health, for the 12-month period ended December 2012, the products garnered annual sales of $176 million.

Glenmark's current portfolio consists of 85 products authorised for distribution in the US market.

Shares of Glenmark were trading at Rs 555 on the BSE in late afternoon trade, up 1.34% from their previous close.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 15 2013 | 3:53 PM IST

Next Story